StockNews.AI
CI
StockNews.AI
90 days

Evernorth Launches New Benefit Option That Drives Lower Net Cost for Weight Loss Medicines and Limits Patient Cost to No More Than $200 Per Month

1. Evernorth's new offering caps weight loss medication costs at $200 monthly. 2. Patients can save up to $3,600 annually compared to manufacturer programs. 3. The initiative enhances safety and simplifies access to medications. 4. Health plan sponsors will experience significant cost reductions per prescription. 5. Evernorth expands its GLP-1 solutions, driving innovation in healthcare access.

7m saved
Insight
Article

FAQ

Why Bullish?

The cost savings and innovative offerings have the potential to attract more clients, improving revenue. Historically, such initiatives tend to increase stock prices, as seen with other health service providers like UnitedHealth Group during their expansions.

How important is it?

The article shows how Evernorth's efforts address critical healthcare needs, indicating a sustainable advantage for CI in a growing market.

Why Long Term?

This initiative will likely enhance Evernorth's competitive edge and revenue in the long run, similar to how value-driven offerings have positively impacted similar firms.

Related Companies

UNHHSICANTMCVS
Patients can save as much as $3600 per year versus direct-to-consumer manufacturer programs, and out of pocket cost applies to their annual deductible New offering helps employers meet growing demand for FDA-approved weight loss medications at a lower net cost per prescription while ensuring clinical safety for patients , /PRNewswire/ -- Evernorth, the health services division of The Cigna Group (NYSE: CI) announced a first-of-its-kind pharmacy benefit offering that make weight loss medications WEGOVY® and ZEPBOUND® more available to patients. Through direct negotiations with the medications' manufacturers, Evernorth has ensured that patients' monthly cost will not exceed $200. "We are reimagining pharmacy benefits to reduce costs and better serve patients," said Adam Kautzner, Pharm D, President of Evernorth Care Management and Express Scripts. "This is what Express Scripts does better than anyone: save Americans money on their prescriptions while helping them achieve their health goals."  This initiative fills a critical need in the market by offering savings, choice and predictability to both patients and health plan sponsors. Benefits for Patients: Lower Monthly Copays than Cash Programs: The monthly copay for GLP-1 weight loss medicines will be limited to no more than $200, which will have the added benefit of counting towards the patient's annual deductible. Meaningful Savings: Patients can save as much as $3,600 per year compared to buying these medications directly from manufacturers or through consumer programs. Enhanced Safety and Efficacy: By accessing WEGOVY® or ZEPBOUND® through Evernorth's pharmacy benefit, patients will benefit from FDA-approved medications and Express Scripts' robust safety checks designed to reduce negative or adverse drug interactions. Simplified Approval and Access: The prior authorization processes accompanying the new offering will be simplified and automated for faster access. Choice of Pharmacies: Patients can select from a broad network of local retail pharmacies or home delivery through Evernorth's EnGuide Pharmacy, staffed by clinicians with specialized knowledge in GLP-1s for enhanced support. Benefits for Employers & Other Health Plan Sponsors: Significant Cost Reduction: Health plan sponsors will see a significant reduction in the net cost per prescription of GLP-1 medications. Offering Patient Options: Health plan sponsors can ensure that patients have access to the medication that works best for them, without compromising affordability or clinical safety. "As advocates for the millions of people we serve, we drive lower medication costs through negotiations with the pharmaceutical manufacturers, and we're making it easier than ever for health plan sponsors to cover GLP-1s for weight loss," said Harold Carter, PharmD, senior vice president of trade relations at Express Scripts. "This is how we deliver on our promise to put patients first - by making innovative medicines more accessible, at a lower cost, while providing patients and physicians choices in this fast-evolving market." Evernorth has the most extensive suite of GLP-1 solutions available with this new addition, which also includes: EncircleRx, a financial model with more than 9 million enrolled lives that has saved health plans $200 million dollars since 2024. EnReachRx, a high-touch patient support clinical model for dispensing GLP-1 prescription medications. About Evernorth Health Services Evernorth Health Services creates pharmacy, care, and benefits solutions to improve health and increase vitality. We relentlessly innovate to make the prediction, prevention, and treatment of illness and disease more accessible to millions of people. Evernorth capabilities are powered by our businesses, including Express Scripts, Express Scripts® Pharmacy, Accredo, eviCore, and MDLIVE, along with holistic Evernorth platforms and solutions that move people and organizations forward. All Evernorth solutions are serviced and provided by or through operating affiliates of Evernorth Health, a wholly owned subsidiary of The Cigna Group (NYSE: CI), or third-party partners. Learn more at evernorth.com. Media Contact:Justine Sessions[email protected]860-810-6523 SOURCE Evernorth WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In

Related News